The intricate dance of cellular development in the nervous system is a captivating subject, and a recent study from MIT's Horvitz lab has shed light on a key player in this complex process. The focus is on a protein complex called cohesin, which, as the title suggests, acts as a shaper of DNA structure, influencing the development of neurons in both worms and humans. This discovery not only deepens our understanding of neurodevelopment but also offers a glimmer of hope for treating a rare developmental disorder, Cornelia de Lange syndrome.
The study, led by MIT postdoc Dongyeop Lee, delves into the role of cohesin in shaping the identity of neurons in the tiny worm C. elegans. The worm's nervous system, comprising just 118 classes of neurons, provides a simpler model for understanding neurodevelopment compared to the human brain's thousands of cell types. Lee's research began with a genetic mutation in C. elegans that led to an overproduction of adrenergic neurons, which are crucial for the worm's response to its environment and internal state.
The coh-1 gene, encoding a part of the cohesin complex, was found to be responsible for this excess. When Lee disrupted cohesin function through other mutations, he observed a similar outcome: an overproduction of adrenergic neurons. This led to a crucial discovery - cohesin, in collaboration with the gene-regulating protein EOR-1 (PLZF in humans), directs neurons to develop into GABA-producing neurons. The structure of the genome, manipulated by cohesin, influences how these regulators interact with DNA.
Lee's experiments revealed a fascinating dichotomy: when cohesin or EOR-1 failed to function, cells that should have become GABA-producing neurons instead became adrenergic neurons. This molecular switch-like behavior of cohesin highlights the importance of genomic DNA structure in neuronal fate determination. The study also noted other developmental defects in cohesin-mutated worms, mirroring aspects of Cornelia de Lange syndrome, a rare genetic disorder.
Cornelia de Lange syndrome, often caused by cohesin gene mutations, presents a compelling connection to the findings. Lee's observations in worms open up new avenues for studying the disease and identifying potential therapeutic targets in C. elegans. The Horvitz lab has already made progress, finding suppressor mutations that counteract cohesin impairment, improving worm health. The team is now focused on identifying the genes where these mutations occur, aiming to translate these findings into potential human therapies.
The study's implications extend beyond the treatment of rare disorders. It suggests a broader role for cohesin in shaping the fates of various neuron types and opens up new avenues of research. Lee emphasizes that this is just the beginning, and the team is eager to explore the full scope of cohesin's influence on neurodevelopment, potentially uncovering new biological insights and therapeutic opportunities.
